Technology ID
TAB-1556

Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms

E-Numbers
E-117-2006-0
Lead Inventor
Lobanenkov, Victor (NIAID)
Applications
Therapeutics
Diagnostics
Therapeutic Areas
Oncology
Immunology
Development Status
The technology is currently in the pre-clinical stage of development.
Lead IC
NIAID
ICs
NIAID
This technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative splice variants were expressed at different levels in all types of cancers, other expressed forms are specific to particular cancer(s).
Commercial Applications
  • Simple, rapid, RT-PCR based diagnostic test to detect BORIS isoforms in cancer patients.
  • Profiling of BORIS splice variants can be useful as a diagnostic tool for the detection of cancers.
  • BORIS can be a therapeutic target antigen for immunotherapeutic and/or siRNA based treatments for cancer.
  • BORIS can be used in combination with other established immunogens for immunotherapeutic treatment of several cancers.

Request More Info

Licensing Contact:
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

Patents

  • Patent Cooperation Treaty
    (PCT) PCT/US2007/77281
    Filed on 2007-08-30
    Status: Expired
  • US
    Provisional (PRV) 60/841,342
    Filed on 2006-08-31
    Status: Abandoned
  • US Patent 8,206,933
    Filed on 2009-02-26
    Status: Issued
  • US Patent 8,440,415
    Filed on 2012-05-23
    Status: Issued

Collaborations

  • Licensing
  • Collaboration

License Status

  • Available for exclusive and non-exclusive licensing.

Collaboration Description

  • The NIAID Laboratory of Immunopathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods of cancer diagnostics and treatment based on detection of BORIS isoforms. Please contact Cecilia Pazman at pazmance@niaid.nih.gov or (301) 451-3526 for more information.
Date Published